NYSE$BHVN
Biohaven Ltd old · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for Q4 2022 and provided a review of recent accomplishments and anticipated upcoming milestones.
Biohaven Ltd. reported a net loss of $201.1 million for the three months ended December 31, 2022. As of December 31, 2022, the company had cash and equivalents of $465.3 million and no debt. The company is focused on advancing its pipeline of therapies for neurological and neuropsychiatric diseases.
- Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global (ex-China) rights.
- Completed Phase 1 SAD/MAD study with BHV-7000 from Kv7 ion channel activator platform and reported preliminary safety and tolerability data.
- Commenced enrollment in pivotal Phase 3 study with myostatin targeting agent, adnectin taldefgrobep alfa, for spinal muscular atrophy.
- Presented preclinical data from IgG degrader, BHV-1300, showing robust reduction of IgG levels.
Headline financials
Revenue & EPS history
Biohaven · Revenue · Quarterly
-$215M
Forward guidance
Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders and expects to reach significant pipeline milestones in the coming periods.
Tailwinds
- Initiate EEG study with BHV-7000 in the first half of 2023
- Submit IND with BHV-7010 in epilepsy and mood disorders in the second half of 2023
- Submit IND with BHV-2100 in chronic pain in 2023
- Commence Phase 1 studies with BHV-8000 in 2023
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q4 2022
-0.5%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+7.7%
Avg return
30 days after
50%
7 / 14 earnings
Positive
+12.6%
Q2 2024
Best reaction
-12.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -9.7% | -16.0% | -17.0% | |
| Q3 2024 | -6.5% | +0.5% | +28.3% | |
| Q3 2025 | -5.7% | +0.5% | +28.3% | |
| Q2 2025 | -9.0% | +6.6% | -5.0% | |
| Q1 2025 | +0.0% | -3.7% | -5.2% | |
| Q4 2024 | -2.2% | -7.1% | -36.3% | |
| Q2 2024 | +12.6% | +13.7% | +6.7% | |
| Q1 2024 | -12.5% | -8.7% | -17.5% | |
| Q4 2023 | +4.7% | +24.0% | +15.6% | |
| Q3 2023 | +1.0% | +4.6% | +30.9% | |
| Q2 2023 | +3.1% | +3.4% | -3.3% | |
| Q1 2023 | +5.3% | +2.2% | +72.6% | |
| Q4 2022 | +10.4% | +5.4% | +10.8% | |
| Q3 2022 | +1.2% | +2.2% | -0.9% | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro